vs

Side-by-side financial comparison of Ceribell, Inc. (CBLL) and CONMED Corp (CNMD). Click either name above to swap in a different company.

CONMED Corp is the larger business by last-quarter revenue ($373.2M vs $24.8M, roughly 15.1× Ceribell, Inc.). CONMED Corp produced more free cash flow last quarter ($41.2M vs $-11.0M).

Ceribell, Inc. develops and commercializes innovative portable neurodiagnostic medical devices, focused on rapid non-invasive electroencephalogram (EEG) solutions for seizure detection. Its core products serve hospital emergency departments, intensive care units, and long-term care facilities, with primary markets across North America and ongoing global expansion efforts.

The CONMED Corporation is a publicly traded American manufacturer of medical equipment and surgical devices, primarily in the orthopedic, laparoscopic and general surgery, and patient care areas. CONMED's headquarters is in Largo, Florida. Prior to July 2022, it was in Utica, New York. CONMED embraces a people-first culture that starts with a mission to support their healthcare partners and the patients they serve. They have manufacturing facilities in the United States and Mexico, offices in...

CBLL vs CNMD — Head-to-Head

Bigger by revenue
CNMD
CNMD
15.1× larger
CNMD
$373.2M
$24.8M
CBLL
More free cash flow
CNMD
CNMD
$52.2M more FCF
CNMD
$41.2M
$-11.0M
CBLL

Income Statement — Q4 2025 vs Q4 2025

Metric
CBLL
CBLL
CNMD
CNMD
Revenue
$24.8M
$373.2M
Net Profit
$-13.5M
Gross Margin
87.3%
58.5%
Operating Margin
-58.9%
9.8%
Net Margin
-54.6%
Revenue YoY
7.9%
Net Profit YoY
EPS (diluted)
$-0.35
$0.54

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBLL
CBLL
CNMD
CNMD
Q4 25
$24.8M
$373.2M
Q3 25
$22.6M
$337.9M
Q2 25
$21.2M
$342.3M
Q1 25
$20.5M
$321.3M
Q4 24
$345.9M
Q3 24
$17.2M
$316.7M
Q2 24
$332.1M
Q1 24
$312.3M
Net Profit
CBLL
CBLL
CNMD
CNMD
Q4 25
$-13.5M
Q3 25
$-13.5M
$2.9M
Q2 25
$-13.6M
$21.4M
Q1 25
$-12.8M
$6.0M
Q4 24
Q3 24
$-10.4M
$49.0M
Q2 24
$30.0M
Q1 24
$19.7M
Gross Margin
CBLL
CBLL
CNMD
CNMD
Q4 25
87.3%
58.5%
Q3 25
88.3%
49.2%
Q2 25
88.1%
55.0%
Q1 25
87.9%
55.3%
Q4 24
57.3%
Q3 24
87.3%
56.5%
Q2 24
55.3%
Q1 24
55.1%
Operating Margin
CBLL
CBLL
CNMD
CNMD
Q4 25
-58.9%
9.8%
Q3 25
-64.8%
3.5%
Q2 25
-70.5%
11.1%
Q1 25
-69.3%
5.0%
Q4 24
15.2%
Q3 24
-57.8%
20.7%
Q2 24
14.2%
Q1 24
11.2%
Net Margin
CBLL
CBLL
CNMD
CNMD
Q4 25
-54.6%
Q3 25
-59.6%
0.8%
Q2 25
-64.4%
6.3%
Q1 25
-62.4%
1.9%
Q4 24
Q3 24
-60.6%
15.5%
Q2 24
9.0%
Q1 24
6.3%
EPS (diluted)
CBLL
CBLL
CNMD
CNMD
Q4 25
$-0.35
$0.54
Q3 25
$-0.37
$0.09
Q2 25
$-0.38
$0.69
Q1 25
$-0.36
$0.19
Q4 24
$1.09
Q3 24
$-1.85
$1.57
Q2 24
$0.96
Q1 24
$0.63

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBLL
CBLL
CNMD
CNMD
Cash + ST InvestmentsLiquidity on hand
$159.3M
Total DebtLower is stronger
$834.2M
Stockholders' EquityBook value
$155.3M
$1.0B
Total Assets
$195.8M
$2.3B
Debt / EquityLower = less leverage
0.81×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBLL
CBLL
CNMD
CNMD
Q4 25
$159.3M
Q3 25
$168.5M
Q2 25
$177.4M
Q1 25
$182.7M
Q4 24
Q3 24
$14.1M
Q2 24
Q1 24
Total Debt
CBLL
CBLL
CNMD
CNMD
Q4 25
$834.2M
Q3 25
$853.0M
Q2 25
$881.1M
Q1 25
$891.4M
Q4 24
$905.1M
Q3 24
$940.1M
Q2 24
$965.2M
Q1 24
$990.1M
Stockholders' Equity
CBLL
CBLL
CNMD
CNMD
Q4 25
$155.3M
$1.0B
Q3 25
$164.1M
$1.0B
Q2 25
$172.2M
$1.0B
Q1 25
$180.9M
$977.6M
Q4 24
$962.7M
Q3 24
$-136.0M
$932.9M
Q2 24
$881.8M
Q1 24
$854.7M
Total Assets
CBLL
CBLL
CNMD
CNMD
Q4 25
$195.8M
$2.3B
Q3 25
$199.5M
$2.3B
Q2 25
$207.7M
$2.3B
Q1 25
$213.5M
$2.3B
Q4 24
$2.3B
Q3 24
$47.1M
$2.3B
Q2 24
$2.3B
Q1 24
$2.3B
Debt / Equity
CBLL
CBLL
CNMD
CNMD
Q4 25
0.81×
Q3 25
0.85×
Q2 25
0.88×
Q1 25
0.91×
Q4 24
0.94×
Q3 24
1.01×
Q2 24
1.09×
Q1 24
1.16×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBLL
CBLL
CNMD
CNMD
Operating Cash FlowLast quarter
$-10.8M
$46.3M
Free Cash FlowOCF − Capex
$-11.0M
$41.2M
FCF MarginFCF / Revenue
-44.2%
11.0%
Capex IntensityCapex / Revenue
0.7%
1.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-41.6M
$150.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBLL
CBLL
CNMD
CNMD
Q4 25
$-10.8M
$46.3M
Q3 25
$-11.1M
$53.7M
Q2 25
$-7.5M
$29.1M
Q1 25
$-11.4M
$41.5M
Q4 24
$43.3M
Q3 24
$51.2M
Q2 24
$43.3M
Q1 24
$29.1M
Free Cash Flow
CBLL
CBLL
CNMD
CNMD
Q4 25
$-11.0M
$41.2M
Q3 25
$-11.5M
$48.5M
Q2 25
$-7.6M
$23.4M
Q1 25
$-11.6M
$37.8M
Q4 24
$39.3M
Q3 24
$47.8M
Q2 24
$39.7M
Q1 24
$27.1M
FCF Margin
CBLL
CBLL
CNMD
CNMD
Q4 25
-44.2%
11.0%
Q3 25
-50.8%
14.4%
Q2 25
-35.9%
6.8%
Q1 25
-56.4%
11.8%
Q4 24
11.4%
Q3 24
15.1%
Q2 24
12.0%
Q1 24
8.7%
Capex Intensity
CBLL
CBLL
CNMD
CNMD
Q4 25
0.7%
1.4%
Q3 25
1.6%
1.5%
Q2 25
0.3%
1.7%
Q1 25
0.7%
1.2%
Q4 24
1.2%
Q3 24
1.1%
Q2 24
1.1%
Q1 24
0.7%
Cash Conversion
CBLL
CBLL
CNMD
CNMD
Q4 25
Q3 25
18.78×
Q2 25
1.36×
Q1 25
6.88×
Q4 24
Q3 24
1.05×
Q2 24
1.44×
Q1 24
1.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CBLL
CBLL

Products$18.8M76%
Subscription$6.0M24%

CNMD
CNMD

Transferred At Point In Time$358.5M96%
Transferred Over Time$14.7M4%

Related Comparisons